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Abstract
Background: Dysregulaiton of phosphate homeostasis as occurs in chronic kidney disease is associated with cardiovascular
complications. It has been suggested that both hyperphosphatemia and hypophosphatemia can cause cardiovascular
disease. The molecular mechanisms by which high or low serum phosphate levels adversely affect cardiovascular function
are poorly understood. The purpose of this study was to explore the mechanisms of endothelial dysfunction in the presence
of non-physiologic phosphate levels.
Methodology/Principal Findings: We studied the effects of simulated hyper- and hypophosphatemia in human umbilical
vein endothelial cells in vitro. We found both simulated hyperphosphatemia and hypophosphatemia decrease eNOS
expression and NO production. This was associated with reduced intracellular calcium, increased protein kinase C b2
(PKCb2), reduced cell viability, and increased apoptosis. While simulated hyperphosphatemia was associated with decreased
Akt/p-Akt, Bcl-xl/Bax ratios, NFkB-p65 and p-Erk abundance, simulated hypophosphatemia was associated with increased
Akt/p-Akt and Bcl-xl/Bax ratios and p-Mek, p38, and p-p38 abundance.
Conclusions/Significance: This is the first demonstration of endothelial dysfunction with hypophosphatemia. Our data
suggests that both hyperphosphatemia and hypophosphatemia decrease eNOS activity via reduced intracellular calcium
and increased PKCb2. Hyperphosphatemia also appears to reduce eNOS transcription via reduced signaling through PI3K/
Akt/NF-kB and MAPK/NF-kB pathways. On the other hand, hypophosphatemia appears to activate these pathways. Our data
provides the basis for further studies to elucidate the relationship between altered phosphate homeostasis and
cardiovascular disease. As a corollary, our data suggests that the level of phosphate in the culture media, if not in the
physiologic range, may inadvertently affect experimental results.
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Introduction
Phosphate is an essential mineral that is a necessary component
of DNA and RNA, is essential for cellular metabolism as an energy
source in the form of ATP, and is critical for proper bone
development. Serum phosphate levels are regulated by an
interplay of dietary intake, parathormone (PTH), 1,25-dihydrox-
yvitamin D, and fibroblast growth factor 23 (FGF23) that act on
the intestine, skeleton, and kidneys [1]. Of these, the kidney is the
major site for minute-to-minute regulation of phosphate homeo-
stasis; approximately 70% of the filtered phosphate is reabsorbed
within the proximal tubule where the sodium-phosphate co-
transporters Npt2a and Npt2c are expressed. PTH reduces the
expression of Npt2a and Npt2c in the apical membrane of the
proximal tubule [1]. High PTH levels, as in hyperparathyroidism,
lead to renal phosphate wasting and hypophosphatemia, while low
PTH levels, as in hypoparathyroidism, lead to increased renal
phosphate reabsoption and hyperphosphatemia. Similar to PTH,
FGF23 suppresses phosphate reabsorption in the proximal tubule.
However, PTH and FGF23 have opposite effects on 1,25-
dihydroxyvitamin D production. PTH increases and FGF23
decreases the proximal renal tubular expression of 25-hydro-
xyvitamin D 1a-hydroxylase that catalyzes the conversion of 25-
hydroxyvitamin D to 1,25-dihydroxyvitamin D. The latter in turn
regulates serum phosphate concentration by increasing intestinal
calcium and phosphate absorption [1].
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e23268Chronic kidney disease (CKD) is associated with accelerated
atherosclerosis, hypertension and increased incidence of death from
myocardial infarction, stroke, and heart failure [2]. Several factors
contribute to the pathogenesis of CKD-induced atherosclerosis and
cardiovascular disease; these include oxidative stress, inflammation,
dyslipidemia and hypertension [3,4,5,6]. In addition, dysregulation of
phosphatehomeostasis,acommonfeatureofCKD,cancontributeto
the cardiovascular complications. In an earlier study Tonelli et al [7]
found a graded independent relation between higher levels of serum
phosphate and the risk of death and cardiovascular events among
people with prior myocardial infarction, most of whom had serum
phosphate levels within the normal range. They further showed that
elevatedserumphosphatelevelswereassociatedwithincreasedriskof
new-onset heart failure, myocardial infarction, and the composite of
coronary death or nonfatal myocardial infarction [7]. Hyperphos-
phatemia has been shown to induce acute endothelial dysfunction in
vivo and exposure to a phosphorus load has been shown to increase
reactive oxygen species production, induce apoptosis, and decrease
nitric oxide (NO) production in endothelial cells in vitro [8,9]. The
decreased NO production may occur because of inactivation of
endothelial nitric oxide synthase (eNOS) caused by phosphorylation
at Thr497 viaactivationofproteinkinase C (PKC)by phosphate. In a
double-blind crossover study, flow-mediated brachial artery dilation
wasmeasured before and twohoursafter meals containing 400 mgor
1200 mg of phosphorus. The higher dietary phosphorus load
increased serum phosphate at two hours and significantly reduced
flow-mediated brachial artery dilation indicating a causal relation
between endothelial dysfunction and acute postprandial hyperphos-
phatemia [10]. On the other hand, hypophosphatemia can also cause
cardiovascular disease including heart failure after cardiac surgery
and cardiac arrest in patients undergoing treatment for diabetic
ketoacidosis with hypertriglyceridemia [11,12]. Hypertension and
metabolic syndrome are also associated with hypophosphatemia and
increased risk of cardiovascular disease [13]. Hypophosphatemiamay
lead to a decreased intracellular inorganic phosphate and mitochron-
drial dysfunction leading to decreased ATP synthesis [13].
Endothelial dysfunction is a common and critical step in the
development of cardiovascular diseases [14,15]. In endothelial cells,
NO is produced from L-arginine and molecular oxygen by the
constitutively expressed eNOS. NO is a potent vasodilator and a key
determinant of cardiovascular homeostasis by virtue of its role in
regulation of arterial blood pressure, vascular remodeling, and
angiogenesis as well as its anti-inflammatory and anti-thrombotic
actions [16]. Endothelial dysfunction is characterized by reduced
eNOS activity and/or expression and decreased NO availability,
which is typical of patients with cardiovascular disease [17]. The
activity of eNOS is regulated by multiple mechanisms that include
transcriptional and epigenetic regulation of mRNA, and post-
translational regulation of the protein by reversible palmitoylation
and caveolar targeting, intracellular calcium levels and calmodulin
binding, reversible phosphorylation of serine and threonine residues,
and reversible S-nitrosylation [18,19,20]. Of note, phosphorylation at
Ser-1177, Ser-635, and Ser-617 are stimulatory, while phosphory-
lation at Thr-495 and Ser-116 are inhibitory [20]. The stimulatory
phosphorylation of eNOS residues Ser-1177 and Ser-617 occur in
response to flow shear stress that activates phosphatidyl-inositol 3-
kinase (PI3K) and its downstream serine/threonine protein kinase,
Akt, which in turn phosphorylates eNOS (PI3K-Akt-eNOS pathway)
[16,21,22]. On the other hand, inhibitory phosphorylation of eNOS
at Thr497 occurs via activation of PKC. In endothelial cells, the
transcription of eNOS is also regulated by shear stress. Shear stress
functions via Src to activate a mitogen-activated protein kinase
(MAPK) pathway that includes Ras, Raf/MEK, and ERK1/2. The
end-result is the activation of the transcription factor nuclear factor
(NF)-kB and initiation of eNOS transcription. Further, signal
transduction through the high-density lipoprotein (HDL) and
estrogen membrane receptors activates the PI3K-Akt pathway via
Src/Ras. While Akt can produce stimulatory phosphorylations of
eNOS, it might also activate NF-kB, which in turn can initiate eNOS
transcription [23,24,25].
The mechanisms by which high or low serum phosphate levels
adversely affect cardiovascular function are poorly understood. Since
NO and eNOS play a major role in vascular physiology, we studied
the effects of low and high phosphate levels on eNOS expression and
NO production in vitro in human umbilical vein endothelial cells
(HUVECs) and also explored the in vitro mechanisms that might
regulate eNOS expression and NO production.
Results
Effect of phosphate concentration on endothelial cell
growth, apoptosis, eNOS expression, and NO production
To evaluate endothelial function, we examined the effect of
exposure to different concentrations of inorganic phosphate for
24 hours on endothelial cell proliferation, apoptosis, eNOS
expression, and NO production. Incubation in media simulating
both hypophosphatemia (0.5 mM) and hyperphosphatemia
(3 mM phosphate) resulted in a significant reduction of cell
numbers when compared to cells incubated in the medium
containing 1 mM phosphate (Figure 1A). While the viable cells
were reduced significantly in both simulated hypo- and hyperpho-
sphatemic conditions when compared with those in normal
phosphate level (Fig 1B), the necrotic cells were significantly
increased only in hyperphosphatemia (Figure 1C). The cell
proliferation/viability data were confirmed by the MTT assay
(data not shown). Similarly, incubation in media simulating both
hypophosphatemia (0.5 mM) and hyperphosphatemia (3 mM
phosphate) resulted in a significant increase in apoptotic cells
when compared to cells incubated in the medium containing
1 mM phosphate (Figure 1D–G). Incubation with pan-caspase
inhibitor z-VAD resulted in significant reduction in apoptosis
induced by both simulated hyperphosphatemia and hypophos-
phatemia (Figure 2 A–F). The cells incubated in media containing
0.5 mM or 3 mM phosphate showed significant reduction in
eNOS abundance (Figure 3A) accompanied by parallel reductions
in NO production (Figure 3B). The down-regulation of eNOS
following exposure to simulated hyperphosphatemia (3 mM
phosphate) was reversed with co-administration of 1 mM PFA,
which is a specific inhibitor of phosphate transport across the cell
membrane [26] (Figure 3C). Incubation in medium with 1 mM
phosphate resulted in a significant NO production 5 minute post
acetylcholine stimulation and remained elevated at 15 minutes. In
contrast, incubation in media simulating both hypophosphatemia
(0.5 mM) and hyperphosphatemia (3 mM phosphate) completely
prevented acetylcholine-induced stimulation of NO generation,
pointing to endothelial dysfunction (Fig 3D). Interestingly,
simulated hyperphosphatemia and hypophosphatemia showed
no effects on survival in normal human lung fibroblasts (Fig 4).
Targeted proteomics analysis data
To explore the mechanism of endothelial dysfunction induced
by non-physiologic levels of inorganic phosphate, we screened the
cells for levels of selected phosphorylated signaling proteins using
reverse-phase protein microarray. Figure 5A shows the reverse-
phase protein microarray heat map of key molecules in various
signaling pathways. Figure 5B shows the quantitative signaling
protein expression in the endothelial cells incubated for 24 hour
with different phosphate concentrations from 0.5 mM to 3.0 mM.
Phosphate and Endothelial Function
PLoS ONE | www.plosone.org 2 August 2011 | Volume 6 | Issue 8 | e23268Figure 1. Effect of inorganic phosphate on endothelial cell proliferation and apoptosis. We examined the effect of exposure to different
concentrations of inorganic phosphate for 24 hours on human umbilical vein endothelial cell proliferation and apoptosis. In Figure 1A, cell number is
determined by light microscopy counting of trypan blue-excluding cells, whereas B–D pertain to flow analysis. Incubation in media simulating
hypophosphatemia (0.5 mM) or hyperphosphatemia (3 mM phosphate) resulted in a significant reduction of cell numbers (A), decreased cell viability
(B) and increased cell dearth (C, statistically significant only seen in hyperphosphatemia) when compared to cells incubated in the medium
containing 1 mM phosphate. Similarly, incubation in media simulating hypophosphatemia (0.5 mM, D & E) or hyperphosphatemia (3 mM phosphate,
D & G) resulted in a significant increase in apoptotic cells when compared to cells incubated in the medium containing 1 mM phosphate (D & F). In
Figure E–G, data in each quadrant are the percentage of total cells, and shown as mean +/2 SEM. p values vs control (1 mM phosphate). N=6,9.
doi:10.1371/journal.pone.0023268.g001
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(1.0 mM), those exposed to simulated hyperphosphatemia (3 mM)
showed significantly reduced levels of eNOS, cyclin D3, Akt, p-
SAPK, p-Erk, p53, PP2A, NF-kB-p65, p-IkB, and Bcl-xl (with
decreased Bcl-xl/Bax ratio), but significantly increased level of
PKCb2. On the other hand, the cells exposed to simulated
hypophosphatemia (0.5 mM) showed significantly decreased level
of eNOS, but significantly increased levels of CDK2, Akt, p-Akt,
p-Mek, p38, p-p38, p53, PP2A, Stat1, p-PLCg2, and PKCb2, and
increased Bcl-xl/Bax ratio.
To validate the reverse-phase protein microarray data, we
examined the protein expression for p-Akt, NF-kB-p65, Bcl-xL and
Bax using routine Western blot. As shown in Figure 6, Western
blotting confirmed the results of reverse-phase protein microarray.
Compared to the control cells exposed to physiologic phosphate
level (1.0 mM), the cells exposed to simulated hypophospatemia
(0.5 mM) showed significantly increased p-Akt, while the cells
exposed to simulated hyperphospatemia (3 mM) showed signifi-
cantly reduced p-Akt, NF-kB-p65 and Bcl-xL. The levels of Bax
were not significantly different between the three groups.
Figure 2. Effect of pan-caspase inhibitor z-VAD in preventing apoptosis caused by simulated hypophosphatemia and
hyperphosphatemia. To further define the role of inorganic phosphate on human umbilical vein endothelial cell apoptosis, a pan-caspase
inhibitor z-VAD (40 uM) was added to the medium containing various concentrations of phosphate. Incubation with pan-caspase inhibitor z-VAD
prevented apoptosis induced by both simulated hyperphosphatemia and hypophosphatemia (Figure 2 A–F). B: hypophosphatemia (0.5 mM); C:
hypophosphatemia (0.5 mM) plus z-VAD; D: phosphate (1 mM); E: hyperphosphatemia (3 mM phosphate); F: hyperphosphatemia (3 mM) plus z-VAD.
In Figure B–F, data in each quadrant are the percentage of total cells, and shown as mean +/2 SEM. p values vs control (1 mM phosphate). N=6,9.
doi:10.1371/journal.pone.0023268.g002
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PI3K/Akt inhibitor, Ly492002 [27], was used to explore the
role of altered Akt in the endothelial dysfunction induced by
simulated hypophosphatemia. Ly492002 had no effect on
increased apoptosis induced by low phosphate levels (Figure 7
A–E). LY492002 resulted in decreased cell viability in hypophos-
phatemia. It led to decreased cell viability and increased cell
necrosis in physiologic phosphate levels (Figure 7 F & G). On the
Figure 3. Effect of inorganic phosphate on eNOS expression and NO production. We examined the effect of exposure to different
concentrations of inorganic phosphate for 24 hours on NO production and eNOS expression. Incubation in media simulating hypophosphatemia
(0.5 mM) or hyperphosphatemia (3 mM phosphate) resulted in a significant reduction in eNOS expression (A) and NO production (B). The down-
regulation of eNOS following exposure to simulated hyperphosphatemia (3 mM phosphate) was reversed with co-administration of 1 mM PFA, which
is a specific inhibitor of phosphate transport across the cell membrane (C). To determine whether abnormal phosphate levels affected the ability of
acetylcholine (a physiological activator of eNOS) to stimulate NO production, a set of cells was incubated with 2 mM acetylcholine and the
supernatant NO levels before (0 minute) and 5 minute and 15 minute post acetylcholine stimulation was measured. As shown in (D), incubation in
medium with 1 mM phosphate resulted in a significant NO production 5 minute post acetylcholine stimulation and remained elevated at 15 minutes.
In contrast, incubation in media simulating both hypophosphatemia (0.5 mM) and hyperphosphatemia (3 mM phosphate) completely prevented
acetylcholine-induced stimulation of NO generation, pointing to endothelial dysfunction. p values vs control (1 mM phosphate). N=6,10.
doi:10.1371/journal.pone.0023268.g003
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expression induced by simulated hypophospatemia but had no
effect on eNOS expression in cells exposed to physiologic
phosphate levels (Figure 7H).
Intracellular calcium
To study the underlying mechanism of endothelial injury
induced by non-physiologic phosphate levels, we studied the effect
of phosphate levels on intracellular free calcium in live cells.
Significant percentage changes in intracellular calcium fluorescent
intensity were observed, respectively, in cells exposed to simulated
hypophosphatemia (27.660.58 vs. 0.0460.039, n=5) and in cells
exposed to simulated hyperphosphatemia (213.361.18 vs.
1.0260.31, n=5) when compared to the normal saline control.
The decrease in intracellular calcium fluorescent intensity in cells
exposed to simulated hyperphosphatemia was almost completely
blocked when the cells were pre-incubated with PFA, a specific
inhibitor of phosphate transport across the cell membrane
(20.34461.601 vs. 20.01460.320. n=7) (Figure 8).
Discussion
Both hypophosphatemia and hyperphosphatemia are associated
with adverse cardiovascular events. However, the underlying
molecular mechanisms of these complications are not fully
understood. Endothelial dysfunction is a common and critical
step in the development of cardiovascular diseases and is
characterized by reduced eNOS activity and/or expression and
decreased NO availability, which is typical of patients with
cardiovascular disease [17]. In this study, we show that exposure to
both subphysiologic and supraphysiologic concentrations of
phosphate reduce eNOS expression and NO production in
HUVECs in vitro. The simulated hyperphosphatemia-induced
down-regulation of eNOS expression could be reversed by co-
treatment with PFA, which is a specific inhibitor of phosphate
transport across the cell membrane. This indicates that the
decreased eNOS expression in HUVECs exposed to simulated
hyperphosphatemia is mediated by an abnormal rise in intracel-
lular phosphate. This is consistent with the results reported by
Shuto et al [10] who showed that high phosphate loading
decreased NO production in brachial artery endothelial cells.
They further showed that high phosphate loading activated
protein kinase C (PKC), which inhibited the activity of eNOS
by phosphorylating the Thr-495 residue of eNOS [10,28].
Consistent with this previously reported result, we found that
simulated hyperphosphatemia significantly increased the level of
PKCb2. In addition, we demonstrate that simulated hyperphos-
phatemia significantly reduced Akt abundance in the endothelial
cells. The stimulatory phosphorylation of eNOS residues Ser-1177
and Ser-617 occur in response to flow shear stress that activates
phosphatidyl-inositol 3-kinase (PI3K) and its downstream serine/
threonine protein kinase Akt, which in turn phosphorylates eNOS
(PI3K-Akt-eNOS pathway) [16,21,22]. Given the critical role of
PI3K-Akt signaling in eNOS activation, the observed down-
regulation of Akt can further diminish endothelial NO production
in a hyperphosphatemic state. Further, it is known that increased
intracellular phosphate levels lead to decreased calcium release
from sarcomplasmic reticulum in muscle cells [29,30]. A similar
mechanism operates in endothelial cells as shown by our data of
reduced intracellular free calcium in the presence of simulated
hyperphosphatemia. Intracellular calcium level and calmodulin
binding are critical determinants of eNOS activity [31,32]. In
addition, we observed decreased NF-kB-p65 and p-Erk abundance
in the presence of simulated hyperphosphatemia. It is known that
the transcription factor NF-kB initiates eNOS transcription. In the
endothelial cells, the activation of NF-kB may occur with sheer
stress via activation of a MAPK pathway that includes Erk1/2 or
through the HDL and estrogen membrane receptor mediated
PI3K-Akt pathway [23,24,25]. Therefore, hyperphosphatemia
may reduce eNOS activity and NO production via multiple
mechanisms. A limitation of our in vitro study is that it cannot take
into account the effect of endocrine and paracrine factors such as
FGF23, PTH, vitamin D, and calcium on phosphate homeostasis
and endothelial function in vitro. Shuto et al studied the effects of
hyperphosphatemia both in vitro and in vitro and showed that
oxidative stress and decreased NO production in endothelial cells
are possible mechanisms for the impaired endothelial function
mediated by phosphate loading [10]. We did not study the
production of reactive oxygen species in our experimental system.
Our study is the first to demonstrate that subnormal levels of
phosphate reduce eNOS expression and NO production in
HUVECs. In this regard, the effect of simulated hypophosphate-
mia on eNOS expression and NO production in HUVECs are
similar to those seen with simulated hyperphosphatemia. Also
similar to simulated hyperphosphatemia, simulated hypophospha-
temia reduced intracellular free calcium and increased PKCb2
level in HUVECs. As discussed earlier, both reduced intracellular
free calcium and increased PKC would be expected to reduce
eNOS activity and therefore NO production. However, surpris-
ingly, simulated hypophosphatemia increased Akt and p-Akt levels
in the endothelial cells. Similarly, we found that simulated
hypophosphatemia increased the levels of p-Mek, p38, and p-
p38, which are components of the MAPK pathway. Therefore, it
appears that, in contrast to simulated hyperphosphatemia,
simulated hypophosphatemia leads to increased PI3K/Akt and
MAPK signaling, which would be expected to activate NF-kB and
lead NF-kB-mediated eNOS transcription. Interestingly, the
experiment with PI3K/Akt inhibitor Ly492002 suggests that the
effect of simulated hypophosphatemia on eNOS expression may
be Akt dependent. Therefore, it appears that other, yet unknown,
Figure 4. Effect of inorganic phosphate on normal human lung
fibroblast proliferation. We examined the effect of exposure to
different concentrations of inorganic phosphate for 24 hours on normal
human lung fibroblast proliferation. The cell proliferation/viability were
validated by the mitochondria-dependent reduction of MTT [3-(4,5-
dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide] to purple
formazan as detailed in the Method section. Incubation in media
simulating hypophosphatemia (0.5 mM) or hyperphosphatemia (3 mM
phosphate) had no effect on fibroblast survival when compared to cells
incubated in the medium containing 1 mM phosphate.
doi:10.1371/journal.pone.0023268.g004
Phosphate and Endothelial Function
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endothelial cells incubated with subphysiologic concentrations of
phosphate.
In HUVECs, both simulated hyperphosphatemia and simulated
hypophosphatemia reduced endothelial cell proliferation and
increased endothelial cell apoptosis. The latter is confirmed by
the fact that pan-caspase inhibitor z-VAD resulted in significant
reduction in apoptosis in both simulated hyper- and hypo-
phosphatemia. Interestingly, simulated hyper- and hypo-phospha-
temia did not affect the survival of normal human lung fibroblasts.
The over-expression of the anti-apoptotic Bcl-xl protein blocks the
release of cytochrome c, while the pro-apoptotic Bax protein
promotes cytochrome c release from the mitochondria in response
to apoptotic signals. The released cytochrome c then activates the
initiator caspase-9, thereby initiating the sequential activation of
downstream caspases leading to apoptosis [33,34]. Compared to
the HUVECs incubated with physiologic phosphate level, those
exposed to simulated hyperphosphatemia showed significantly
reduced levels of Bcl-xl and decreased the ratio of the anti-
apoptotic Bcl-xl to the pro-apoptotic Bax. This suggests that
endothelial cell apoptosis induced by hyperphosphatemia may act
through downregulation of Bcl-xl. On the other hand, the cells
exposed to simulated hypophosphatemia showed significantly
increased ratio of the anti-apoptotic Bcl-xl to the pro-apoptotic
Bax, suggesting that the mechanism of endothelial apoptosis in the
setting of hypophosphatemia is different. The cells exposed to
simulated hypophosphatemia showed elevated level of p53 (and
the reverse was true for the cells exposed to simulated
hyperphosphatemia) indicating that the apoptosis in the presence
of low phosphate levels may be driven by p53. The non-
physiologic levels of phosphate also affect the cell cycle regulatory
proteins such as cyclin D3 and cyclin dependent kinase 2 (CDK2).
While simulated hyperphosphatemia led to a decrease in the level
of cyclin D3, simulated hypophosphatemia led to an increase in
the level of CDK2 in HUVECs. Pertinently, CDK2 has been
shown to play a role in inducing apoptosis and acts upstream of
p53 [35,36]. A similar CDK2-p53 dependent apoptosis may occur
in the presence of hypophosphatemia. Further exploration of the
alterations in cell cycle machinery in the presence of altered
phosphate levels are needed to fully explain the reduced
proliferation of HUVECs seen in our study. The effect of
simulated hyper- and hypo-phosphatemia on endothelial cell
proliferation and apoptosis indeed suggest that physiologic
phosphate levels are critical for intracellular homeostasis and cell
viability. These effects are likely mechanistically complex and not
surprising given that phosphate is an essential component of DNA
and RNA and is vital for cellular metabolism as an energy source
in the form of ATP. In addition, numerous functional proteins
(including caspase family of cysteine proteases that mediate
apoptosis) that are essential to cellular signaling and homeostasis
are activated or inactivated by reversible phosphorlyation/
dephosphorylation processes catalyzed by various kinases/phos-
phatases [37,38].
Our study utilized the relatively new and powerful technique of
reverse phase protein array to analyze the alterations of signaling
proteins in HUVECs exposed to different concentrations of
phosphate. Reverse phase protein arrays are designed for
quantitative, multiplexed analysis of specific active (phosphorylat-
ed, cleaved) or total forms of cellular proteins using a limited
amount of sample including tissues, cells, and body fluids [39].
Reverse phase proteins arrays are more sensitive than enzyme
linked immunosorbent assays (ELISA) with lower limit of detection
in the attogram range and the ability to detect variances of ,10%.
Further, reverse phase proteins arrays do not require direct
labeling of sample proteins and utilization of a two-site antibody
sandwich, thereby reducing experimental variability [40,41,
42,43].
Given the results of this study, we would like to emphasize that
researchers should pay close attention to the levels of phosphate in
the culture media and adjust the level, if needed, so that phosphate
is in the physiologic range. Otherwise, many molecular and
biochemical processes might be affected unrelated to the
experiments being performed.
In summary, we show that both simulated hyperphosphatemia
and hypophosphatemia decrease eNOS expression and NO
production in HUVECs and are associated with endothelial cell
death. Our data provides further insights on the complex




Human umbilical vein endothelial cells (HUVECs), purchased
from Bio Whittaker (San Diego, CA, USA) were cultured in EGM
endothelial cell growth medium (Lonza, Walkersville, MD) in a
humidified incubator set at 37uC and 5% CO2. Once a monolayer
was formed, the cells were subcultured. For the experiments, cells
with no more than eight passages were used. Once reaching 90–95%
confluence, the cells were subcultured in 60615 mm BD Falcon
tissue culture dishes (BD Biosciences, Franklin Lakes, NJ, USA) and
incubated for 48–72 hours, at which point 85–90% confluence was
reached. The cells were then rinsed with fresh medium and
incubated with media containing differentphosphateconcentrations.
Normal human lung fibroblasts (NHLF, Cat# CC-2512) were
cultured in medium supplied by the manufacturer (Lonza).
Study design
The physiologic range of serum phosphate concentration is
approximately 0.9–1.5 mM. The EGM medium contains 0.5 mM
phosphate (Lonza, Walkersville, MD). It was supplemented with
appropriate amounts of sodium phosphate buffer (1 M Na2HPO4/
NaH2PO4, pH 7.4) to achieve final inorganic phosphorus
concentrations of 1.0, 1.5, 2.0, and 3.0 mM, respectively. 1 mM
phosphonoformic acid (PFA) (Sigma, St Louis, MO, USA), a
specific inhibitor of the sodium-phosphate transporter, was used to
block phosphate transport into the cells. To determine whether
Figure 5. Effect of inorganic phosphate on cell signaling protein expression. Using reverse-phase protein microarray, we examined the
effect of exposure to different concentrations of inorganic phosphate for 24 hours on human umbilical vein endothelial cell signaling protein
expression. (A): shows the reverse-phase protein microarray heat map of key molecules for signaling pathway (green represents expression below
median and red represents above-median expression). (B): shows the quantitative signaling protein expression in the endothelial cells incubated for
24 hour with different phosphate concentrations from 0.5 mM to 3.0 mM. Compared to the cells incubated with physiologic phosphate level
(1.0 mM), those exposed to simulated hyperphosphatemia (3 mM) showed significantly reduced eNOS, cyclin D3, Akt, p-SAPK, p-Erk, p53, PP2A, NF-
kB-p65, p-IkB, Bcl-xl , and Bcl-xl/Bax ratio, but significantly increased level of PKCb2. On the other hand, the cells exposed to simulated
hypophosphatemia (0.5 mM) showed significantly decreased level of eNOS, but significantly increased CDK2, Akt, p-Akt, p-Mek, p38, p-p38, p53,
PP2A, Stat1, p-PLCg2, PKCb2, and Bcl-xl/Bax ratio. *p,0.05, **p,0.01 vs control (1 mM phosphate).
doi:10.1371/journal.pone.0023268.g005
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PLoS ONE | www.plosone.org 8 August 2011 | Volume 6 | Issue 8 | e23268abnormal phosphate levels affected the ability of acetylcholine (a
physiological activator of eNOS) to stimulate NO production, a set
of cells was incubated with 2 mM acetylcholine and the
supernatant NO levels before (baseline) and 5 minute and 15
minute post acetylcholine stimulation was measured.
Western blot analysis
Western blotting was performed as previously described [44].
The following primary antibodies were used: anti-eNOS (1:5000,
BD Biosciences), anti-p-Akt (1:2000, Cell Signaling, Danvers,
MA, USA), anti-NF-kB-p65 (1:5000, Abcam, Cambridge, UK),
Figure 6. Western blot analysis of p-Akt, NFkB, Bcl-xL and Bax expressions. To validate the reverse-phase protein microarray data, we
examined the protein expression for p-Akt, NF-kB-p65, Bcl-xL and Bax using western blot. Compared to the control cells exposed to physiologic
phosphate level (1.0 mM), the cells exposed to simulated hypophospatemia (0.5 mM) showed significantly increased p-Akt (A), while the cells
exposed to simulated hyperphospatemia (3 mM) showed significantly reduced p-Akt (A), NF-kB-p65 (B) and Bcl-xL (C). The levels of Bax were not
significantly different between the three groups (D). P values vs control (1 mM phosphate). N=4,8.
doi:10.1371/journal.pone.0023268.g006
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PLoS ONE | www.plosone.org 10 August 2011 | Volume 6 | Issue 8 | e23268anti-Bax (1:2000, Cell Signaling) and ant-BcL-xL (1:2000, Cell
Signaling). Briefly, the protein content of the treated HUVEC
lysate was measured using the BCA assay (Pierce Biotechnology,
Rockford, IL, USA) and 20 mg total protein was size-fractionated
on 4–12% Tris-glycine gel (BD Biosciences) at 100 V for 2 h.
After electrophoresis, the proteins were transferred to nitrocellu-
lose membrane (Hybond-ECL, Amersham, Buckinghamshire,
UK) at 350 mA for 2.5 h using the Novex transfer system
(Invitrogen, Carlsbad, CA, USA). The membrane was prehy-
bridized in 10 ml blocking buffer (10 mmol/l Tris-HCl, pH 7.5,
100 mmol/l NaCl, 0.1% Tween-20, and 10% nonfat milk
powder) for 1 hour (room temperature) and then hybridized for
an additional 12 hours at 4uC in the same buffer with added
primary antibody. Then the membrane was washed for 30 min in
a shaking bath; the wash buffer (Tris-buffered saline Tween 20)
was changed every 10 min for 3 times. Then the membrane was
incubated for 1 hour with block buffer plus secondary antibody
tagged with horseradish peroxidase at the final titer of 1:5000.
The washes were repeated before the membrane was developed
with a light emitting nonradioactive method using ECL reagent
(SuperSignal West Dura kit, Thermo Scientific, Rockford, IL,
USA). The membrane was then subjected to autoluminography
for 5 min. The respective band intensities were measured using
Scion Image (WinB403; http://rsb.info.nih.gov/index). In all
instances, the membranes were stained with Ponceau stain, which
verified the uniformity of protein load and transfer efficiency
across the test samples.
Apoptosis assay
Apoptotic cells were determined by staining with the Annexin
V-PE Apoptosis Kit (BD, Pharmingen), which employs a FITC-
labeled annexin V (Annexin V-FITC) in concert with 7-Amino-
actinomycin D (7-AAD) to evaluate subpopulations of cells
undergoing apoptosis. Briefly, after 24-hour incubation in the
medium described above, the cells were digested with 0.05%
Trypsin-EDTA (Invitrogen, Carlsbad, CA, USA) for 1 min,
harvested using the medium containing 2% FBS, and collected by
centrifugation (200 g) at 4uC. The cells were re-suspended at a
final concentration of 2610
7 cells/ml. 2610
5 cells (100 ml) were
washed with cold staining buffer (PBS with calcium and
magnesium supplemented with 0.5% FCS and 0.5% NaN3)
and then incubated with 5 ml annexin V-FITC and 5 ml7 - A A D
in 100 ml staining buffer, for 15 min, at 4uC, in the dark. Cells
were washed again, gently re-suspended in 250 ml staining buffer.
Cell samples were analyzed by flow cytometry on a FACScan
flow cytometer (Becton-Dickinson, Mountain View, CA, USA)
and ten thousand events were counted. Live cells are Annexin-V-
ve, 7-AAD-ve; necrotic cells are Annexin-V-ve, 7-AAD+ve;
apoptotic cells are Annexin-V+ve, 7-AAD-ve (early apoptosis)
or Annexin-V+ve, 7-AAD+ve (late apoptosis) [45,46]. To
separate apoptosis from necrosis, a pan-caspase inhibitor, z-
VAD (40 uM; Cat# N-1510, Z-Val-Ala-DL-Asp-fluoromethylk-
etone) [47] was added to the media with simulated hypophos-
phatemia (0.5 mM) or simulated hyperphosphatemia (3.0 mM)
for 24 hrs and flow cytometry analyses were performed as
described above.
Cell proliferation studies
The cell number was determined by a Counting Chamber (Levy
Counting Chamber, Hausser Scientific, Horsham, PA, USA). For
counting the cells, cultured cell samples were digested with 0.05%
trypsin-EDTA, harvested using the medium with 2% FBS, and
collected by centrifugation (2006g) for 5 min at 4uC. Cells were re-
suspended with 1 ml culture medium and thoroughly mixed. 100 ml
of suspension cells was used to count the number of cells. In
addition, cell proliferation/viability were validated by the mito-
chondria-dependent reduction of MTT [3-(4,5-dimethylthiazol-2-
yl)-2, 5-diphenyl tetrazolium bromide] (Sigma) to purple formazan.
Briefly, cells were seeded on to 96 well culture plates and treated
with different concentrations of phosphate for 24 h. After the
treatment, 100 ug MTT reagent was added to each well. After 4 h
of incubation, the supernatant was carefully removed and 150 mlo f
dimethyl sulfoxide solution was added to dissolve the formazan
crystals. After shaking for 10 min on a plate mini-shaker, the
absorbance at 570 nm was read on a microplate reader.
Measurement of NO
NO production was assessed bymeasurement ofNO metabolites,
nitrates plus nitrites, in the cell culture media using QuantiChrom
Nitric Oxide Assay Kit (BioAssay Systems, Hayward, CA)
according to the manufacturer’s instructions. This assay is based
onthereductionofnitratetonitritebycadmiumandthe subsequent
detection of nitrite with the Griess reagent which is specific for
nitrite. The detection range is 0.1–50 uM in 96-well plate.
Reverse phase protein array
Reverse phase protein array was used to query the HUVEC
lysates for signaling proteins as described previously [48,49,50].
Antibodies to Akt, p-AKT, p-Stat3, P38, p-P38, p-ErK1,2, p-Bad,
E2F1, p-PLCr2, p-IkB, p-Mek, NF-kB-p65, p-PTEN, Bcl-xL, Bax
and p-STAT3 were purchased from Cell Signaling. Antibodies to
eNOS, PP2A, CDK1, CDK2, cyclin D3, Stat1, p53, and PKCb2
were purchased from BD Biosciences. Antibody to b-actin was
purchased from Epitomics. All antibodies were used at dilutions of
1:250–1000. HUVECS cultured in media containing various
concentrations of phosphate were harvested and lysed. Protein
concentrations of the lysates were determined using the BCA assay
(Pierce Biotechnology, Rockford, IL, USA). All lysates, each in
four dilutions (neat, 1:3, 1:9, 1:27, 1:81) were arrayed on
nitrocellulose coated glass slides and stored at 280uC till further
analysis. The slides were blocked and then incubated with the
primary antibodies. After incubating with biotinylated secondary
antibody, the array slides were developed with the Dako signal
amplification system using catalyzed reporter deposition of
substrate (Dako, Carpinteria, CA, USA). The developed slides
were scanned as TIFF files and the signals analyzed with
Imagequant TL (GE Healthcare, Wauwatosa, Wisconsin, USA).
b-actin was used as a loading control to normalize data.
Measurement of intracellular free calcium
To investigate the effect of phosphate on intracellular free
calcium in live cells, the fluo-3 acetoxymethyl (AM) (Fluo3-AM)
Figure 7. Effect of Akt pathway on endothelial function. We used PI3K/Akt inhibitor, Ly492002, to explore the role of altered Akt in the
endothelial dysfunction induced by simulated hypophosphatemia. Ly492002 had no effect on increased apoptosis induced by low phosphate levels
(Figure 5A–E). LY492002 resulted in decreased cell viability in hypophosphatemia. It led to decreased cell viability and increased cell death in
physiologic phosphate levels (Figure 5 F & G). On the other hand, Ly492002 was able to block the reduction of eNOS expression induced by simulated
hypophospatemia but had no effect on eNOS expression in cells exposed to physiologic phosphate levels (Figure 5H). In Figure A–D, data in each
quadrant are the percentage of total cells, and shown as mean +/2 SEM. A: 0.5 mM phosphate; B: 1 mM phosphatre; C: 0.5 mM
phosphate+Ly492002; D: 1.0 mM phosphate+Ly492002.
doi:10.1371/journal.pone.0023268.g007
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poly-D-lysine-coated coverslips in 2.562.5 cm
2 well tissue culture
and maintained in a humidified incubator at 37uCi na n
atmosphere of 5% CO2 in air. Once a monolayer reached 50–
60% confluence, the cells were rinsed and incubated in Fluo3-AM
calcium dye (Molecular Probes, Eugene, OR) for 15 min at 37uC
and excess dye was removed. For confocal studies, dye-loaded
endothelial cells on coverslips were incubated with culture medium
with normal phosphate (1.0 mM), followed by normal saline
(control) or simulated hypophosphatemia (0.5 mM) or simulated
hyperphosphatemia (3.0 mM) and PFA. A baseline reading of dye-
loaded cells was measured with a fluorometer at 485 nm emission/
530 nm excitation (Perseptive Biosystems, Stafford, TX). The
experimental reading was taken continuously, and raw data were
collected for 10 second intervals. The percent changes in
fluorescence were calculated and graphed using the Origin
macroanalysis software. Five wells were used for each treatment,
and individual responses were averaged to represent the value for
a single experiment. All experiment procedures were performed in
less than 5 minutes.
Statistical Analyses
Data are presented as mean 6 SEM. Analysis of variance
(ANOVA) and Student’s t-test were used in statistical evaluation of
the data as appropriate. P-values less than or equal to 0.05 were
considered significant.
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